Ohio State Navbar

Directory

Jeffrey Jones, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 688-7942

Email: jones.2685@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Clinical Interest

Hematology, Medical Oncology

Academic Advising

2010 - present Emily Dotson The Ohio State University. Graduated 2011.
2011 - present Galena Salem Ohio State University College of Medicine. Graduated 2013.
2013 - present Kerry Rogers Ohio State University College of Medicine.
2008 The Ohio State University.
2006 - 2010 Cory Darrow The Ohio State University. Graduated 2010.
2009 - 2010 Samantha Jaglowski The Ohio State University. Graduated 2010.
2010 The Ohio State University.
 

Certifications

2003 - present Board Certification: American Board of Internal Medicine
2004 - present Fundamental Critical Care Support: MD Anderson Medical Center
2006 - present Medical License: State Medical Board of Ohio
2006 - present Board Certification: American Board of Internal Medicine
2006 - present Board Certification: American Board of Internal Medicine
2006 - present Certificate: American Heart Association
2006 - present Certificate: American Heart Association
2000 - 2003 Quebec Resident Training Card: College des Medecins du Quebec
2004 Certificate: National Cancer Institute
2003 - 2006 Medical License: Texas Medical Board
 

Conferences

Andritsos,Leslie,A; Jones,Jeffrey; Lozanski,Gerard; Lin,Thomas,S; Blum,Kristie,A; Grever,Michael,R; Jarjoura,David; Byrd,John,C; Heerema,Nyla. "Del(17p13.1) in chronic lympliucytic leukemia confers poor prognosis even at low percentage involvement and increases proportionately with. increase in clonal involvement." In BLOOD. (November 2007). 617A-618A.

Andritsos,Leslie,A; Fischer,Beth; Lin,Thomas,S; Blum,Kristie,A; Jones,Jeffrey,A; Moran,Mollie,E; Byrd,John,C; Grever,Michael,R. "Low incidence of opportunistic infections in CLL patients treated with single agent flavopiridol." In BLOOD. (November 2007). 920A-920A.

Heerema,Nyla,A; Byrd,John,C; Andritsos,Leslie,A; Lozanski,Gerard; Blum,Kristie; Fischer,Beth; Jones,Jeffrey,A; Moran,Mollie,E; Groering,Sarah; Schaaf,Larry,J; Mahoney,Linda,S; Johnson,Amy,J; Smith,Lisa,L; Wagner,Amy,J; Raymond,Chelsey,A; Phelps,Mitch,A; Dalton,James,T; Grever,Michael,R; Lin,Thomas,S. "Clinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patients (Pts).." In BLOOD. (November 2007). 914A-914A.

Lin,Thomas,S; Fischer,Beth; Blum,Kristie,A; Andritsos,Leslie,A; Jones,Jeffrey,A; Moran,Mollie,E; Broering,Sarah; Heerema,Nyla,A; Lozanski,Gerard; Schaaf,Larry,J; Mahoney,Linda,S; Johnson,Amy,J; Smith,Lisa,L; Wagner,Amy,J; Raymond,Chelsey,A; Phelps,Mitch; Dalton,James,T; Grever,Michael,R; Byrd,John,C. "Preliminary results of a phase II study of flavopiridol (Alvocidib) in, relapsed chronic lymphocytic leukemia (CLL): Confirmation of clinical activity in high-risk patients and achievement of complete responses (CR).." In BLOOD. (November 2007). 913A-913A.

Jones,Jeffrey,Alan; Byrd,John,C; Flynn,Joseph,M; Hofmeister,Craig. "Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care." In BLOOD. (November 2008). 840-840.

Benson,Don; Andritsos,Leslie; Hamadani,Mehdi; Lin,Thomas; Flynn,Joseph; Jones,Jeffrey; Blum,William; Elder,Patrick; Lozanski,Gerard; Byrd,John; Devine,Steven. "Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation.." In BLOOD. (November 2008). 1133-1134.

Lin,T,S; Andritsos,L,A; Jones,J,A; Fischer,B; Heerema,N,A; Blum,K,A; Flynn,J,M; Moran,M,E; Phelps,M,A; Grever,M,R; Byrd,J,C. "Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)." In JOURNAL OF CLINICAL ONCOLOGY. (May 2008). n/a-.

Jones,Jeffrey,Alan; Flynn,Joseph,M; Byrd,John,C. "Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM)." In BLOOD. (November 2008). 323-323.

Flynn,J,M; Andritsos,L,A; Lin,T,S; Byrd,J,C; Jones,J,A. "Second primary malignancies after chronic lymphocytic leukemia." In JOURNAL OF CLINICAL ONCOLOGY. (May 2008). n/a-.

Andritsos,Leslie; Hamadani,Mehdi; Heerema,Nyla,A; Benson,Don; Hofmeister,Craig,C; Blum,William; Flynn,Joseph; Jones,Jeffrey,Alan; Elder,Patrick; Lin,Thomas,S; Lozanski,Gerard; Byrd,John,C; Devine,Steven. "Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)." In BLOOD. (November 2008). 756-757.

Jones,Jeffrey,A; Qazilbash,Muzaffar,H; Shih,Ya-Chen,I; Cantor,Scoff,B; Cooksley,Catherine,D; Elting,Linda,S. "In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies - Clinical and economic outcomes from the nationwide inpatient sample." In Cancer. (March 2008). 1096-1105.

May,Sarah,E; Kashishian,Adam; Lin,Thomas,S; Jones,Jeffrey,A; Flynn,Joseph,M; Ulrich,Roger,G; Chen,Hao; Yu,Albert,S; Puri,Kamal,D; Lannutti,Brian,J; Giese,Neill,A; Byrd,John,C; Johnson,Amy,J. "CAL-101, a Selective Inhibitor of the p110 delta Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease." In BLOOD. (November 2008). 1085-1086.

Lin,Thomas,S; Heerema,Nyla,A; Lozanski,Gerard; Fischer,Beth; Blum,Kristie,A; Andritsos,Leslie,A; Jones,Jeffrey,A; Flynn,Joseph,M; Moran,Mollie,E; Mitchell,Sarah; Johnson,Amy,J; Phelps,Mitch,A; Grever,Michael,R; Byrd,John,C. "Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities." In BLOOD. (November 2008). 23-24.

Blum,Kristie,A; Liu,Zhongfa; Lucas,David,M; Baiocchi,Robert; Lin,Thomas,S; Benson,Don; Devine,Steven,M; Jones,Jeffrey; Andritsos,Leslie; Flynn,Joseph; Cheng,Ping; Xic,Zhiliang; Marcucci,Guido; Chan,Kenneth,K; Grever,Michael,R; Byrd,John,C. "A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation." In BLOOD. (November 2008). 1087-1087.

Blum,Kristie,A; Baiocchi,Robert,A; Alinari,Lapo; Lin,Thomas,S; Porcu,Pierluigi; Jones,Jeffrey; Flynn,Joseph; Hicks,William; Lucas,Margaret,S; Wei,Lai; Johnston,Jeffrey,S; Byrd,John,C. "A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma." In BLOOD. (November 2008). 1049-1050.

Heerema,N,A; Lin,T,S; Fischer,B; Lozanski,G; Blum,K,A; Andritsos,L,A; Jones,J,A; Flynn,J,M; Moran,M,E; Mitchell,S,M; Schaaf,L,J; Johnson,A,J; Smith,L,L; Wagner,A,J; Raymond,C,A; Phelps,M; Dalton,J,T; Grever,M,R; Byrd,J,C. "Chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetics respond to treatment with flavopiridol: Study of 120 patients (pts) with relapsed, genetically high risk CLL." In CYTOGENETIC AND GENOME RESEARCH. (January 2008). n/a-.

Tsimberidou,Apostolia-Maria; Wierda,William; Plunkett,William; O'Brien,Susan; Kipps,Thomas,J; Jones,Jeffrey,Alan; Smith,Susan; Jalayer,Annette; Kantarjian,Hagop,M; Keating,Michael. "Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).." In BLOOD. (November 2009). 1337-1338.

Jaglowski,Samantha,M; Byrd,John,C; Jones,Jeffrey,A. "In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP).." In BLOOD. (November 2009). 569-570.

Jones,J,A; Flynn,J; Moran,M; Lin,T; Byrd,J. "Trends in pneumonia (PNA) hospitalization among patients (pts) with chronic lymphocytic leukemia (CLL)." In JOURNAL OF CLINICAL ONCOLOGY. (May 2009). n/a-.

Woyach,Jennifer,A; Byrd,John,C; Zhao,John; McFaddin,Andrew; Ruppert,Amy,S; Lin,Thomas,S; Andritsos,Leslie; Blum,Kristie,A; Flynn,Joseph,M; Jones,Jeffrey,Alan; Heerema,Nyla,A. "Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease." In BLOOD. (November 2009). 508-508.

Flynn,Joseph,M; Johnson,Amy,J; Andritsos,Leslie; Blum,Kristie,A; Jones,Jeffrey,A; Wiley,Elizabeth,A; Hu,Weihong; Hessler,Joshua; Smith,Lisa,L; Lucas,David,M; Small,Karen; Statkevich,Paul; Grever,Michael,R; Bannerji,Rajat; Byrd,John,C. "The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia." In BLOOD. (November 2009). 365-365.

Awan,Farrukh; Lapalombella,Rosa; Trotta,Rossana; Butchar,Jonathan,P; Yu,Bo; Benson,Don; Cheney,Carolyn; Mo,Xiaokui; Lehman,Amy; Jones,Jeffrey,Alan; Flynn,Joseph,M; Jarjoura,David; Baiocchi,Robert,A; Desjarlais,John; Tridandapani,Susheela; Caligiuri,Michael,A; Muthusamy,Natarajan; Byrd,John,C. "CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody." In BLOOD. (November 2009). 1435-1435.

Grant,Barbara; Leonard,John,P; Johnson,Jeffrey,L; Kostakoglu,Lale; Hsi,Eric; Byrd,John,C; Jones,Jeffrey,A; Jung,Sin-Ho; Cheson,Bruce,D. "Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701-a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)." In BLOOD. (November 2010). 191-191.

Tsimberidou,Apostolia,Maria; Wierda,William,G; Wen,Sijin; Plunkett,William; O'Brien,Susan; Kipps,Thomas,J; Jones,Jeffrey,A; Kantarjian,Hagop,M; Keating,Michael,J. "Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)." In BLOOD. (November 2010). 408-408.

Jaglowski,Samantha,M; Flynn,Joseph,M; Jones,Jeffrey,A; Lin,Thomas,S; Fischer,Beth; Scholl,Diane; Elder,Patrick; Devine,Steven,M; Grever,Michael,R; Byrd,John,C; Andritsos,Leslie. "Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant." In BLOOD. (November 2010). 987-988.

Andritsos,Leslie; Byrd,John,C; Jones,Jeffrey,A; Hewes,Becker; Kipps,Thomas,J; Hsu,Frank,J; Burger,Jan,A. "Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia." In BLOOD. (November 2010). 1017-1017.

Zhao,W,O; Tang,Y; Li,Y; Long,S; Jones,J; Andritsos,L; Flynn,J; Heerema,N; Lozanski,G. "MUTATION STATUS AND PREFERRED UTILIZATION OF IGVH GENE IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATIONS WITH COMMON BIOLOGIC ABNORMALITIES." In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. (June 2010). 518-518.

Kipps,Thomas,J; Wierda,William,G; Jones,Jeffrey,A; Swinnen,Lode,J; Yang,Jianning; Cui,Yue; Busman,Todd; Krivoshik,Andrew; Enschede,Sari; Humerickhouse,Rod. "Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)." In BLOOD. (November 2010). 1019-1019.

Woyach,Jennifer,A; Ruppert,Amy,S; Blum,Kristie,A; Jones,Jeffrey,Alan; Flynn,Joseph,M; Johnson,Amy,J; Grever,Michael,R; Byrd,John,C; Heerema,Nyla,A. "Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities." In BLOOD. (November 2010). 1019-1020.

Stephens,Deborah,M; Ruppert,Amy,S; Blum,Kristie,A; Jones,Jeffrey,A; Flynn,Joseph,M; Johnson,Amy,J; Ji,Jia; Phelps,Mitchell; Grever,Michael,R; Byrd,John,C. "Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients." In BLOOD. (November 2010). 592-593.

Johnson,Amy,J; Smith,Lisa,L; Wagner,Amy,J; Hessler,Joshua; Flynn,Joseph,M; Jones,Jeffrey,A; Zhang,Xiaoli; Lehman,Amy; Jarjoura,David; Grever,Michael,R; Bannerji,Rajat; Byrd,John,C. "Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines." In BLOOD. (November 2010). 428-428.

Hofmeister,Craig,C; Bowers,Mindy,A; Lee,Seungsoo; Phelps,Mitch,A; Benson,Don,M; Kraut,Eric,H; Hicks,William,J; Deam,Deidre; Johnson,Amy,J; Farag,Sherif; Jones,Jeffrey,A; Byrd,John,C. "Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia." In BLOOD. (November 2010). 804-804.

Herman,Sarah,EM; Lapalombella,Rosa; Jones,Jeffrey,A; Andritsos,Leslie; Gordon,Amber,L; Ramanunni,Ashia; Lannutti,Brian; Muthusamy,Natarajan; Byrd,John,C; Johnson,Amy,J. "Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-delta Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia.." In BLOOD. (November 2010). 760-761.

Mahoney,Emilia; Johnson,Amy,J; Wagner,Amy,J; Hessler,Joshua; Gupta,Sneha,V; Herman,Sarah,EM; Andritsos,Leslie; Jones,Jeffrey,A; Flynn,Joseph,M; Lucas,David,M; Grever,Michael,R; Byrd,John,C. "Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol." In BLOOD. (November 2010). 305-305.

Jones,Jeffrey,A; Andritsos,Leslie; Baiocchi,Robert; Benson,Don,M; Blum,Kristie,A; Christian,Beth; Deam,Deidre; Flynn,Joseph,M; Johnson,Amy,J; Phelps,Mitch,A; Porcu,Pierluigi; Byrd,John,C; Grever,Michael,R. "Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma." In BLOOD. (November 2010). 1169-1169.

Baiocchi,Robert,A; Flynn,Joseph,M; Jones,Jeffrey,A; Blum,Kristie,A; Hofmeister,Craig,C; Poon,Jennifer; Small,Karen; Statkevich,Paul; Grever,Michael,R; Bannerji,Rajat; Byrd,John,C. "Early Evidence of Anti-Lymplioma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Heavily Pre-Treated Low Grade Lymphoma and Diffuse Large Cell Lymphoma Patients." In BLOOD. (November 2010). 1618-1618.

Flynn,Joseph,M; Jones,Jeffrey,A; Andritsos,Leslie; Blum,Kristie,A; Johnson,Amy,J; Hessler,Josh; Wiley,Elizabeth; Poon,Jennifer; Small,Karen; Statkevich,Paul; Grever,Michael,R; Bannerji,Rajat; Byrd,John,C. "Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration.." In BLOOD. (November 2010). 600-601.

Christian,Beth; Alinari,Lapo; Earl,Christian,Tyler; Wilding,Emily; Quinion,Carl; Lustberg,Mark; Benson,Don,M; Jones,Jeffrey,A; Byrd,John,C; Wegener,William,A; Goldenberg,David,M; Baiocchi,Robert,A; Blum,Kristie,A. "A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma." In BLOOD. (November 2010). 1148-1149.

Blum,Kristie,A; Ruppert,Amy,S; Woyach,Jennifer,A; Jones,Jeffrey,A; Andritsos,Leslie; Flynn,Joseph,M; Rovin,Brad; Villalona-Calero,Miguel; Ji,Jia; Phelps,Mitchell; Johnson,Amy,J; Greyer,Michael,R; Byrd,John,C. "Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol." In BLOOD. (November 2010). 596-597.

Blum,Kristie,A; Jones,Jeffrey,A; Andritsos,Leslie; Flynn,Joseph,M; Deam,Deidre; Heerema,Nyla,A; Phelps,Mitchell; Johnson,Amy,J; Grever,Michael,R; Byrd,John,C. "Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)." In BLOOD. (November 2010). 1027-1027.

Kipps,Thomas,J; Swinnen,Lode,J; Wierda,William,G; Jones,Jeffrey,Alan; Coutre,Steven,E; Smith,Mitchell,R; Yang,Jainning; Cui,Yue; Busman,Todd; Enschede,Sari; Humerickhouse,Rod. "Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)." In BLOOD. (November 2011). 1669-1669.

Jones,Jeffrey,A; Stark,Amy; Zhao,Weiqiang; Lin,Thomas,S; Rai,Kanti,R; Marcucci,Guido; Peterson,Bercedis; Larson,Richard,A; Heerema,Nyla,A; Byrd,John,C. "Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.." In BLOOD. (November 2011). 781-782.

Flinn,Ian,W; Harwin,William,N; Macias-Perez,Ines,M; Tucker,Patrick,S; Waterhouse,David,M; Papish,Steven,W; Jones,Jeffrey,A; Hainsworth,John,D; Byrd,John,C. "A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma." In BLOOD. (November 2011). 1673-1673.

Tsimberidou,A,M; Wierda,W; Wen,S; Plunkett,W; O'Brien,S; Kipps,T; Jones,J; Kantarjian,H; Keating,M,J. "FINAL RESULTS OF A PHASE I-II CLINICAL TRIAL OF OXALIPLATIN, FLUDARABINE, CYTARABINE, AND RITUXIMAB (OFAR) COMBINATION THERAPY IN PATIENTS WITH AGGRESSIVE, RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND RICHTER SYNDROME (RS)." In ANNALS OF ONCOLOGY. (June 2011). 119-120.

Christian,Beth; Alinari,Lapo; Jones,Jeffrey,A; Benson,Don,M; Flynn,Joseph,M; Porcu,Pierluigi; Lustberg,Mark,E; Phelps,Mitchell; Poi,Ming; Chung,Diana; Quinion,Carl; Byrd,John,C; Wegener,William; Goldenberg,David,M; Baiocchi,Robert,A; Blum,Kristie,A. "Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma." In BLOOD. (November 2011). 1584-1584.

Blum,Kristie,A; Wei,Lai; Jones,Jeffrey,A; Andritsos,Leslie,A; Flynn,Joseph,M; Heerema,Nyla,A; Yang,Xiaoxia; Rozewski,Darlene; Phelps,Mitchell; Johnson,Amy,J; Grever,Michael,R; Byrd,John,C. "Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial." In BLOOD. (November 2011). 1672-1672.

Lapalombella,Rosa; Ramanunni,Asha; Yeh,Yuh-Ying; Wang,Liwen; Jha,Shruti; Staubli,Justin; Herman,Sarah,EM; Andritsos,Leslie,A; Jones,Jeffrey,A; Flynn,Joseph,M; Mo,Xiaokui; Johnson,Amy,J; Thompson,Peter; Algate,Paul,A; Stromatt,Scott; Freitas,Michael,A; Muthusamy,Natarajan; Byrd,John,C. "Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals." In BLOOD. (November 2011). 284-285.

Cohen,Jonathon,B; Hall,Nathan; Ruppert,Amy,S; Jones,Jeffrey,A; Porcu,Pierluigi; Baiocchi,Robert,A; Penza,Sam; Benson,Don,M; Andritsos,Leslie,A; Flynn,Joseph,M; Devine,Steven,M; Blum,Kristie,A. "The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma." In BLOOD. (November 2011). 1345-1346.

aglowski SM, Jones JA, Flynn JM, Andritsos LA Maddocks K, Blum KA, Grever MR, Geyer SM, Woyach J, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC. "A phase Ib/II study evaluating activity and tolerability of the BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic." In J Clin Oncol. (May 2012). Abstr 6508-.

Morrison,Eleshia; Flynn,Joseph,M; Jones,Jeffrey,A; Byrd,John,C; Andersen,Barbara,L. "Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia." In BLOOD. (November 2012). n/a-.

Morrison,Eleshia; Flynn,Joseph,M; Jones,Jeffrey,A; Byrd,John,C; Andersen,Barbara,L. "Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia." In BLOOD. (November 2012). n/a-.

Blum,Kristie,A; Christian,Beth; Flynn,Joseph,M; Jaglowski,Samantha,M; Jones,Jeffrey,Alan; Maddocks,Kami; Byrd,John,C. "A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)." In BLOOD. (November 2012). n/a-.

Mahoney,Emilia; Cole,Sara,L; Maddocks,Kami; Flynn,Joseph,M; Jones,Jeffrey,A; Zhang,Xiaoli; Byrd,John,C; Johnson,Amy,J. "Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies." In BLOOD. (November 2012). n/a-.

Hertlein,Erin,K; Chen,Timothy,L; Claus,Rainer; Plass,Christoph; Lehman,Amy; Jarjoura,David; Maddocks,Kami; Jones,Jeffrey,A; Lucas,David,M; Johnson,Amy,J; Byrd,John,C. "The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia." In BLOOD. (November 2012). n/a-.

Byrd,John,C; Furman,Richard,R; Coutre,Steven; Flinn,Ian,W; Burger,Jan,A; Blum,Kristie,A; Sharman,Jeff; Grant,Barbara; Jones,Jeffrey,A; Wierda,William,G; Zhao,Weiqiang; Heerema,Nyla,A; Johnson,Amy,J; Anh Tran,A; Clow,Fong; Kunkel,Lori; James,Danelle,F; O'Brien,Susan. "The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study." In BLOOD. (November 2012). n/a-.

Hertlein,Erin,K; Chen,Timothy,L; Claus,Rainer; Plass,Christoph; Lehman,Amy; Jarjoura,David; Maddocks,Kami; Jones,Jeffrey,A; Lucas,David,M; Johnson,Amy,J; Byrd,John,C. "The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia." In BLOOD. (November 2012). n/a-.

Cohen,Jonathon,B; Geyer,Susan; Lozanski,Gerard; Zhao,Weiqiang; Heerema,Nyla,A; Jones,Jeffrey,A; Porcu,Pierluigi; Christian,Beth; Baiocchi,Robert,A; Maddocks,Kami; Flynn,Joseph,M; Devine,Steven,M; Blum,Kristie,A. "Complete Response (CR) to Induction Therapy in Patients (pts) with Myc plus and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).." In BLOOD. (November 2012). n/a-.

Cohen,J,B; Ruppert,A,S; Kaplan,L,D; Baiocchi,R; Porcu,P; Flynn,J; Penza,S; Jones,J,A; Blum,K,A; Devine,S,M; Andritsos,L,A. "COMPLEX KARYOTYPE (CK) IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE OF RELAPSE (CIR) FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE CELL LYMPHOMA (MCL) IN FIRST REMISSION." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2012). S205-S206.

Maddocks,Kami; Hertlein,Erin,K; Flynn,Joseph,M; Andritsos,Leslie,A; Wagner,Amy,J; Chen,Timothy,L; Phelps,Mitch,A; Grever,Michael,R; Johnson,Amy,J; Byrd,John,C; Jones,Jeffrey,A. "A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)." In BLOOD. (November 2012). n/a-.

Dubovsky,Jason,A; Beckwith,Kyle,A; Woyach,Jennifer,A; Jaglowski,Samantha,M; Hessler,Joshua; Chang,Betty,Y; Larkin,Karilyn; Stefanovski,Matthew,R; Frissora,Frank,W; Smith,Lisa,L; Smucker,Kelly,A; Flynn,Joseph,M; Jones,Jeffrey,A; Andritsos,Leslie,A; Maddocks,Kami; Lehman,Amy; Furman,Richard,R; Sharman,Jeff; Mishra,Anjali; Caligiuri,Michael,A; Buggy,Joseph,J; Muthusamy,Natarajan; Johnson,Amy,J; Byrd,John,C. "Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells." In BLOOD. (November 2012). n/a-.

Cohen,Jonathon,B; Ruppert,Amy,S; Heerema,Nyla,A; Jones,Jeffrey,A; Porcu,Pierluigi; Baiocchi,Robert,A; Christian,Beth; Byrd,John,C; Flynn,Joseph,M; Penza,Sam; Andritsos,Leslie,A; Devine,Steven,M; Blum,Kristie,A. "Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).." In BLOOD. (November 2012). n/a-.

SALEM,G; Dunavin,N; Wei,L; Elder,P; Penza,S; Blum,K; Porcu,P; Baiocchi,R; Jones,J; Flynn,J; Andritsos,L; Devine,S,M; Christian,B; Efebera,Y. "Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity." In BONE MARROW TRANSPLANTATION. (April 2012). S84-S85.

 

Degrees

1992 B.A., University of Maryland

1992 B.A., University of Maryland

2000 M.D., University of Michigan

2006 M.Public Hlth., The University of Texas Health Science Center at Houston

 

Editorial Activities

2008 - present Leukemia and Lymphoma
2009 - present Cancer
2009 - present Drugs
2009 - present Stem Cells & Development
2010 - present Expert Review of Hematology
2010 - present Diabetes Research and Clinical Practice
2013 - present Clinical Lymphoma, Myeloma, and Leukemia
2013 - present American Journal of Clinical and Experimental Immunology
 

Honors

1992 Phi Beta Kappa.
1992 Commencement Speaker.
1992 - 1998 Maryland Distinguished Scholar.
1996 - 2000 Ralph L. Morse Medical Scholarship.
2000 Alpha Omega Alpha.
2000 - 2001 Eli G. Rochelson Award. University of Michigan Medical School.
2005 - 2006 ASCO Merit Award. ASCO.
2007 - 2008 ASCO Young Investigator Award. ASCO.
2008 - 2009 Outstanding Faculty Educator. OSU Internal Medicine Student Programs.
 

Journal Articles

Rengasamy, A; Kommineni, C; Jones, JA; Fedan, J S. "Effects of hard metal on nitric oxide pathways and airway reactivity to methacholine in rat lungs.." Toxicology and applied pharmacology. Vol. 157, no. 3. (January 1999.): 178-191.

Jones,Jeffrey,A; Avritscher,Elenir,BC; Cooksley,Catherine,D; Michelet,Marisol; Bekele,B,Nebiyou; Elting,Linda,S. "Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. Vol. 14, no. 6. (June 2006.): 505-515.

Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstien JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE. "Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis." Cancer. Vol. ., no. 109. (January 2007.): 820-831.

Jones JA, Qzailbash MH, Shih YT, Cantor SB, Cooksley CD, Elting LS. "In-hospital complications of autologous stem-cell transplant for lymphoid malignancies:economic and clinical outcomes from the Nationwide Inpatient Sample." Cancer. Vol. 112, no. 5. (March 2008.): 1096-1105.

Lin,Thomas,S; Ruppert,Amy,S; Johnson,Amy,J; Fischer,Beth; Heerema,Nyla,A; Andritsos,Leslie,A; Blum,Kristie,A; Flynn,Joseph,M; Jones,Jeffrey,A; Hu,Weihong; Moran,Mollie,E; Mitchell,Sarah,M; Smith,Lisa,L; Wagner,Amy,J; Raymond,Chelsey,A; Schaaf,Larry,J; Phelps,Mitch,A; Villalona-Calero,Miguel,A; Grever,Michael,R; Byrd,John,C. "A Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): High Response Rates in Genetically High-Risk Disease." J Clin Oncol. Vol. 27, no. 35. (December 2009.): 6012-6018.

Hertlein,Erin; Wagner,Amy,J; Jones,Jeffrey; Lin,Thomas,S; Maddocks,Kami,J; Towns,William,H; Goettl,Virginia,M; Zhang,Xiaoli; Jarjoura,David; Raymond,Chelsey,A; West,Derek,A; Croce,Carlo,M; Byrd,John,C; Johnson,Amy,J. "17-DMAG targets the NF-{kappa} B family of proteins to induce apoptosis in CLL: clinical implications of HSP90 inhibition." Blood. Vol. 116, no. 1. (July 2010.): 45-53.

Blum,Kristie,A; Ruppert,Amy,S; Woyach,Jennifer,A; Jones,Jeffrey,A; Andritsos,Leslie; Flynn,Joseph,M; Rovin,Brad; Villalona-Calero,Miguel; Ji,Jia; Phelps,Mitchell; Johnson,Amy,J; Greyer,Michael,R; Byrd,John,C. "Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol." BLOOD. Vol. 116, no. 21. (November 2010.): 596-597.

Herman,Sarah,EM; Gordon,Amber,L; Wagner,Amy,J; Heerema,Nyla,A; Zhao,Weiqiang; Flynn,Joseph,M; Jones,Jeffrey; Andritsos,Leslie; Puri,Kamal,D; Lannutti,Brian,J; Giese,Neill,A; Zhang,Xiaoli; Wei,Lai; Byrd,John,C; Johnson,Amy,J. "Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals." Blood. Vol. 116, no. 12. (September 2010.): 2078-2088.

Blum,Kristie,A; Liu,Zhongfa; Lucas,David,M; Chen,Ping; Xie,Zhiliang; Baiocchi,Robert; Benson,Donald,M; Devine,Steven,M; Jones,Jeffrey; Andritsos,Leslie; Flynn,Joseph; Plass,Christoph; Marcucci,Guido; Chan,Kenneth,K; Grever,Michael,R; Byrd,John,C. "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation." British Journal Of Haematology. Vol. 150, no. 2. (July 2010.): 189-195.

Jones,Jeffrey,A; Fayad,Luis,E; Elting,Linda,S; Rodriguez,Maria,A. "Body mass index and outcomes in patients receiving chemotherapy for untreated intermediate-grade B-cell non-Hodgkin's lymphoma." Leuk Lymphoma. Vol. 51, no. 9. (September 2010.): 1649-1657.

Awan,Farrukh,T; Lapalombella,Rosa; Trotta,Rossana; Butchar,Jonathan,P; Yu,Bo; Benson,Don,M; Roda,Julie,M; Cheney,Carolyn; Mo,Xiaokui; Lehman,Amy; Jones,Jeffrey; Flynn,Joseph; Jarjoura,David; Desjarlais,John,R; Tridandapani,Susheela; Caligiuri,Michael,A; Muthusamy,Natarajan; Byrd,John,C. "CD19 targeting of chronic lymphocytic leukemia with novel Fc-domain-engineered monoclonal antibody." Blood. Vol. 115, no. 6. (February 2010.): 1204-1213.

Woyach,Jennifer,A; Heerema,Nyla,A; Zhao,John; McFaddin,Andrew; Stark,Amy; Lin,Thomas,S; Andritsos,Leslie,A; Blum,Kristie,A; Flynn,Joseph,M; Jones,Jeffrey,A; Byrd,John,C. "Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukemia associated with aggressive disease." Br J Haematol. Vol. 148, no. 5. (March 2010.): 754-759.

Herman,Sarah,EM; Lapalombella,Rosa; Gordon,Amber,L; Ramanunni,Asha; Blum,Kristie,A; Jones,Jeffrey; Zhang,Xiaoli; Lannutti,Brian,J; Puri,Kamal,D; Muthusamy,Natarajan; Byrd,John,C; Johnson,Amy,J. "The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia." Blood. Vol. 117, no. 16. (April 2011.): 4323-4327.

Herman,Sarah,EM; Gordon,Amber,L; Hertlein,Erin; Ramanunni,Asha; Zhang,Xiaoli; Jaglowski,Samantha; Flynn,Joseph; Jones,Jeffrey; Blum,Kristie,A; Buggy,Joseph,J; Hamdy,Ahmed; Johnson,Amy,J; Byrd,John,C. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." Blood. Vol. 117, no. 23. (June 2011.): 6287-6296.

Blum,K,A; Ruppert,A,S; Woyach,J,A; Jones,J,A; Andritsos,L; Flynn,J,M; Rovin,B; Villalona-Calero,M; Ji,J; Phelps,M; Johnson,A,J; Grever,M,R; Byrd,J,C. "Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor flavopiridol." Leukemia. Vol. 25, no. 9. (September 2011.): 1444-1451.

Muthusamy,Natarajan; Breidenbach,Heather; Andritsos,Leslie; Flynn,Joseph; Jones,Jeffrey; Ramanunni,Asha; Mo,Xiaokui; Jarjoura,David; Byrd,John,C; Heerema,Nyla,A. "Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate." Cancer Genetics. Vol. 204, no. 2. (February 2011.): 77-83.

Jaglowski,Samantha; Jones,Jeffrey,A. "Choosing first-line therapy for chronic lymphocytic leukemia." Expert Review of Anticancer Therapy. Vol. 11, no. 9. (September 2011.): 1379-1390.

Jones JA. "Weight gain after lymphoma treatment: fat or fiction?." Leuk Lymphoma. Vol. 11, no. 9. (September 2011.): 1379-1390.

Mahoney,Emilia; Lucas,David,M; Gupta,Sneha,V; Wagner,Amy,J; Herman,Sarah,EM; Smith,Lisa,L; Yeh,Yuh-Ying; Andritsos,Leslie; Jones,Jeffrey,A; Flynn,Joseph,M; Blum,Kristie,A; Zhang,Xiaoli; Lehman,Amy; Kong,Hui; Gurcan,Metin; Grever,Michael,R; Johnson,Amy,J; Byrd,John,C. "ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol." Blood. Vol. 120, no. 6. (August 2012.): 1262-1273.

Stephens,Deborah,M; Ruppert,Amy,S; Blum,Kristie; Jones,Jeffrey; Flynn,Joseph,M; Johnson,Amy,J; Ji,Jia; Phelps,Mitch,A; Grever,Michael,R; Byrd,John,C. "Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach." Haematologica-The Hematology Journal. Vol. 97, no. 3. (March 2012.): 423-427.

Racke,Frederick; Cole,Carol; Walker,Alison; Jones,Jeffrey; Heerema,Nyla,A. "Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification." CANCER GENETICS. Vol. 205, no. 12. (December 2012.): 653-656.

Johnson,A,J; Yeh,Y-Y; Smith,L,L; Wagner,A,J; Hessler,J; Gupta,S; Flynn,J; Jones,J; Zhang,X; Bannerji,R; Grever,M,R; Byrd,J,C. "The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells." LEUKEMIA. Vol. 26, no. 12. (December 2012.): 2554-2557.

Lapalombella,Rosa; Yeh,Yuh-Ying; Wang,Liwen; Ramanunni,Asha; Rafiq,Sarwish; Jha,Shruti; Staubli,Justin; Lucas,David,M; Mani,Rajeswaran; Herman,Sarah,EM; Johnson,Amy,J; Lozanski,Arletta; Andritsos,Leslie; Jones,Jeffrey; Flynn,Joseph,M; Lannutti,Brian; Thompson,Peter; Algate,Paul; Stromatt,Scott; Jarjoura,David; Mo,Xiaokui; Wang,Dasheng; Chen,Ching-Shih; Lozanski,Gerard; Heerema,Nyla,A; Tridandapani,Susheela; Freitas,Michael,A; Muthusamy,Natarajan; Byrd,John,C. "Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals." Cancer Cell. Vol. 21, no. 5. (May 2012.): 694-708.

Jones,Jeffrey,A; Kraut,Eric,H; Deam,Deidre; Byrd,John,C; Grever,Michael,R. "Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia." Leuk Lymphoma. Vol. 53, no. 3. (March 2012.): 490-491.

Jaglowski,Samantha,M; Ruppert,Amy,S; Heerema,Nyla,A; Bingman,Anissa; Flynn,Joseph,M; Grever,Michael,R; Jones,Jeffrey,A; Elder,Patrick; Devine,Steven,M; Byrd,John,C; Andritsos,Leslie,A. "Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia." Br J Haematol. Vol. 159, no. 1. (October 2012.): 82-87.

Woyach,J,A; Lozanski,G; Ruppert,A,S; Lozanski,A; Blum,K,A; Jones,J,A; Flynn,J,M; Johnson,A,J; Grever,M,R; Heerema,N,A; Byrd,J,C. "Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features." Leukemia. Vol. 26, no. 6. (June 2012.): 1442-1444.

Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JC. "Chronic lymphocytic leukemia patients with high-risk genomic features have inferior outcome on successive CALGb trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101." Leuk Lymphoma. -.

Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM, Flynn J, Andritsos LA, Devine SM, Blum KA. "Association of pre-transplantation positron emission tomography/computed tomorgraphy and outcome in mantle cell lymphoma." Bone Marrow Transplant. -.

Byrd JC, Furman RR, Coutre Se, Flinn IW, Burger JA, Blum KA, Grant B, Sharman J, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, and O'Brien S. "Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia." NEJM. -.

Mahoney E, Maddocks R, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC. and Johnson A. "Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies." Leuk Lymphoma. -.

 

Presentations

"Prognostic Factors and Treatment for Chronic Lymphocytic Leukemia: Clinical Strategies in 2008." Presented at Symposium on Lymphoma and Leukemia, Little Rock, AK, US|USA. (September 2008)

"Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions among Patients with Lymphoid Malignancies." Presented at American Society of Hematology Annual Meeting 2008, San Francisco, CA, US|USA. (December 2008)

"New Agents on the Horizon for CLL." Presented at Sixth Annual Symposium on Controversie and Clinical Challenges in Myeloma, Lymphoma, and Leukemia, Phoenix, AZ, US|USA. (September 2009)

"What are the new drugs on the horizon that my patients will ask me about." Presented at 14th Annual Internation Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (March 2010)

"Abrogating the Cell Cycle in Chronic Lymphocytic Leukemia." Presented at 14th Annual International congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (March 2010)

"Role of Old and New Monoclonal Antibodies, Alone and in Combinations." Presented at Hematologic Malignancies 2010, Houston, TX, US|USA. (October 2010)

"New Agents on the Horizon for Chronic Lymphocyic Leukemia." Presented at 7th Annual Synmposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, & Leukemia, Pasadena, CA, US|USA. (September 2010)

"New Agents on the Horizon for Chronic Lymphocytic Leukemia." Presented at Seventh Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma & Leukemia, Pasadena, CA, US|USA. (September 2010)

"Treatment Options for CLL: Emerging Data." Presented at Emerging Data in Hematology, Las Vegas, NV, US|USA. (February 2011)

"Anthracycline-based chemoimmunotherapy + ibrutinb for Richter's transformation of CLL." Presented at CLL Research Consortium Annual Meeting, San Diego, CA, US|USA. (February 2012)

"Should rituximab-bendamustine be utilized as frontline therapy for symptomatic CLL or held in reserve for salvage therapy?." Presented at Great Debates and Updates in Hematologi Malignancies, NY, US|USA. (April 2012)

"17p and 11q deletions in CLL." Presented at Great Debates and Updates in hematologi Malignancies, New York, NY, US|USA. (April 2012)

"The sum of experience from CALGB: Focus on elderly patients." Presented at MabThera/RITUXAN: Leading the way to breakthroughs in haematology, Amsterdam, NL|NLD. (June 2012)

"Phase 1 Study of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (SCH727965) in Relapsed/Refractory CLL." Presented at Europena Hemtaology Associat Annual Meeting 2012, Amsterdam, NL|NLD. (June 2012)

"Inhibition of BTK: A Promising New Approach." Presented at 10th International Congress on Targeted Therapies in Cancer, Washington, DC, US|USA. (August 2012)

"CLL Today: Context for GS-1101 Development." Presented at GS-US-312-0119 INvestigator Meeting, San Francisco, CA, US|USA. (September 2012)

"CLL Therapy, excluding Transplantation: New Targeted Therapies." Presented at American Society of Hematology Annual Meeting 2012, Atlanta, GA, US|USA. (December 2012)

"Novel Agents in Development for Treatment of Patients with CLL." Presented at 16th Annual International Congress on Hematologi Malignancies, Snowbird, UT, US|USA. (February 2012)

"Mechanisms of toxicity of PI3K-delta inhibitors." Presented at 1st Annual Expert Forum on B-cell Receptor Signaling, Santa Monica, CA, US|USA. (February 2013)

"Chronic Lymphocytic Leukemia: Putting on a New Face." Presented at Community Oncology Alliance Conference 2013, Orlando, FL, US|USA. (March 2013)

"Current Standard of Care and Treatment Paradigms: Relapsed/Refractory CLL." Presented at Pharmacyclics Hematology Regional Advisory Board, Dallas, TX, US|USA. (April 2013)

"Recent Advances in Chronic Lymphocytic Leukemia." Presented at Charles L Spurr Piedmont Oncology Spring Symposium, Winston-Salem, NC, US|USA. (May 2013)

"Targeting BTK in Relapsed/Refractory Hairy Cell Leukemia." Presented at Hairy Cell Leukemia Consortium Meeting, New York, NY, US|USA. (May 2013)

"Combination Kinase Inhibitor Therapy for Relapsed/Refractory CLL." Presented at CLL Research Consortium Annual Meeting, San Diego, CA, US|USA. (April 2013)

"Targeting Novel Signaling Pathways in B-cell Malignancies." Presented at NCCN 8th Annual Conference on Hematologic Malignancies, New York, NY, US|USA. (September 2013)

 

Professional Activities

present Invited Speaker. Central Ohio Chapter, Leukemia and Lymphoma Society.
present Invited Speaker. Central Ohio Chapter, Leukemia and Lymphoma Society.
present Academic National Advisory Board. Bristol Myers Squibb.
present Academic National Advisory Board for Ofatumumab in CLL. GlaxoSmithKline.
present Gilead CLL Academic Advisory Board. Gilead Pharmaceuticals.
present New Agents of Interest in Lymphoma Advisory Board. Celgene.
present NCI CLL Working Group.
present Ibrutinib Academic Advisory Board (Mantle Cell lLymphoma indications). Pharmacyclics, Inc..
2011 - 2001 Velcade Advisory Board. Millennium Pharmaceuticals.
 

Unpublished Works

Jones JA, Ruppert AS, Poi M, Phelps M, Andritsos LA, Baiocchi R, Benson D, Blum KA, Christian BA, Flynn J, Penza S, Porcu P, Byrd JC Grever M. Flavopiridol can be safely administered using pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. April 2013.

Grant B, Jung S-H, Johnson J, Kastakgolu L, His E, Byrd JC, Jones JA, Leonard J, Martin S, Cheson B. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. May 2013.

Dubovsky J, Beckwith K, Natarajan G, Woyach J, Jaglowski S, Zhong Y, Hessler J, Lie T-M, Chang B, Larkin K, Stefanovski M, Chappell D, Frissora F, Smith L, Smucker K, Flynn J, Jones J, Andritsos L, Maddocks K, Lehman A, Furman R, Sharman J, Mishra A, Caligiuri M, Satoskar A, Buggy J, Muthusamy N, Johnson A, Byrd J. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. April 2013.

Maddocks KJ, Hertlein EK, Flynn JM, Andritsos LA, Wagner AJ, Chen TL, Phelps MA, Grever MR, Johnson AJ, Byrd JC, and Jones JA. A Phase I Trial of the Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Beckwith KA, Frissora FW, Stefanovski MR, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Byrd JC, and Muthusamy N. The CD37-targeting antibody-drug conjugate IMGN529 is efficacious in a novel human CD37-positive mouse leukemia model.

Andritsos LA, Dunavin N, Lozanski G, Jones JA, Kraut E, Grever MR. Reduced Dose Pentostatin for Initial Management of Hairy Cell Leukemia Patients Who Have Active Infection or Risk of Hemorrhage is Safe and Effective.